查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930090

全球镥-177市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Lutetium-177 Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

镥-177 (Lu-177) 市場成長因素

由於標靶放射性核種療法在腫瘤學領域的應用日益廣泛，全球镥-177 (Lu-177) 市場正經歷快速成長。 根據 Fortune Business Insights 預測，镥-177 市場規模預計在 2025 年達到 27.3 億美元，並在 2026 年達到 34.3 億美元。預計到 2034 年，該市場規模將達到 147 億美元，2026 年至 2034 年的複合年增長率高達 19.95%。

北美地區憑藉較高的癌症發生率、完善的醫保報銷系統以及大型镥-177 生產設施，在全球镥-177 市場佔主導地位，預計到 2025 年將佔 80.95% 的市場佔有率。

市場概覽

镥-177 是一種放射性同位素，廣泛用於標靶放射性核素治療，特別適用於治療攝護腺癌和神經內分泌腫瘤。 透過與前列腺特異性膜抗原 (PSMA) 等特定受體結合，镥-177 可將 β 射線直接輸送至癌細胞，從而最大限度地減少對周圍健康組織的損傷。這些臨床優勢使镥-177 成為精準腫瘤治療的關鍵組成部分。

全球癌症發生率上升、對標靶治療的需求不斷增長以及主要製藥公司強大的研發管線正在推動市場成長。諾華製藥、蘭特斯控股和泰利克斯製藥等領先企業正積極投資臨床試驗和產品拓展。

市場驅動因素

癌症發生率上升

癌症發生率的上升，尤其是前列腺癌和神經內分泌腫瘤的發生率上升，是镥-177 市場的主要驅動因素。 基於 Lu-177 的療法提高了治療的精準度，使其非常適合晚期和轉移性癌症。

例如，根據美國癌症協會估計，到 2025 年，美國將新增 313,780 例前列腺癌病例，隨著需要標靶治療的患者群體不斷擴大，這無疑將推動市場成長。

積極的研發活動

廣泛的研發活動和後期臨床試驗正在進一步加速市場成長。 2023 年 12 月，Lantheus Holdings 與 Point BioPharma 合作，宣布了針對轉移性去勢抵抗性前列腺癌的 177Lu-PNT2002 的 III 期 SPLASH 試驗的積極頂線結果，進一步增強了人們對基於 Lu-177 療法的信心。

市場限制因子

儘管成長前景強勁，但釕-177療法的高昂成本仍然是一個挑戰，尤其是在中低收入國家。放射性藥物生產、專用設施、監管合規和培訓人員等相關費用顯著增加了治療成本。

此外，發展中地區核醫基礎設施的匱乏和不完善的報銷政策阻礙了該療法的廣泛應用。

市場機會

臨床適應症的拓展

越來越多的臨床試驗正在探索釕-177的新治療適應症，這帶來了巨大的成長機會。 新型釕-177候選藥物及其兒科適應症的監管審批正在擴大目標患者群體。

例如，美國食品藥物管理局 (FDA) 授予 Y-mAbs Therapeutics 公司的 177Lu-omburtamab-DTPA 治療罕見兒科疾病的資格認定，凸顯了其在成人腫瘤學以外的未來成長潛力。

市場趨勢

聯合療法的成長

將釕-177 與化療和免疫療法合併應用正成為主要趨勢。聯合療法可以提高療效、降低抗藥性並最大限度地減少輻射劑量。製藥公司在合作開發此類療法方面正獲得越來越多的進展。

細分市場分析

依藥物類型

市場依藥物類型細分：Lutathera、Pluvicto 和其他。

2024年，由於神經內分泌腫瘤發生率的上升，Lutathera（鎧-177）佔了市場主導地位。 Pravict預計將強勁成長，這得益於前列腺癌病例的增加以及健保報銷的批准，包括加拿大於2025年3月正式批准其醫療保險報銷。

依年齡組別劃分

2024年，成人市場佔主導地位，這主要得益於65歲以上人口前列腺癌的高發生率。由於Lu-177療法獲準用於兒童，預計兒童市場將保持穩定成長。

依應用領域劃分

2024年，攝護腺癌領域佔了最大的市場佔有率，這主要得益於疾病發生率的上升和新產品的上市。 由於發病率上升和持續的研發活動，神經內分泌腫瘤領域預計也將顯著成長。

依最終使用者劃分

截至2024年，醫院憑藉其先進的放射性藥物基礎設施和與生物技術公司加強的合作，引領市場。專科診所和研究機構的應用也不斷擴展。

區域洞察

在先進的醫療基礎設施和強有力的報銷政策的推動下，北美镥-177市場在2025年的價值將達到22.1億美元。由於主要製造商和生產設施的所在地，美國仍然是最大的貢獻者。

由於癌症病例數的增加和專業核醫中心的擴張，歐洲佔第二大市場。由於癌症發生率上升、臨床試驗的擴展以及對放射性藥物研究投資的增加，亞太地區預計將成為成長最快的地區。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家/地區主要疾病流行情形（2025 年）
  • 主要公司產品線分析
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情對市場的影響

第五章 全球镥-177 市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依藥物分類
    • Lutathera（镥-177 氧曲肽）
    • Pruvikt（镥-177 比匹博肽四氫西坦）
    • 其他
  • 市場分析、洞察與預測：依年齡組別分類
    • 成人
    • 兒童
  • 市場分析、洞察與預測：依應用分類
    • 神經內分泌腫瘤
    • 攝護腺癌
    • 其他
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區 (ROW)

第六章：北美鎧-177市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲镥-177市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第八章 亞太地區镥-177市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 世界其他地區（ROW）镥-177市場分析：洞察與預測（2021-2034）

第十章 競爭分析

  • 全球市佔率分析（2025）
  • 公司型材
    • Novartis AG
    • Telix Pharmaceuticals Limited
    • Ariceum Therapeutics
    • Radiopharm Theranostics Limited
    • Lantheus Holdings, Inc.
    • Y-mAbs Therapeutics, Inc.
    • GLYTHERIX
    • Curium
Product Code: FBI112740

Growth Factors of lutetium-177 (Lu-177) Market

The global lutetium-177 (Lu-177) market is witnessing rapid expansion due to the growing adoption of targeted radionuclide therapies in oncology. According to Fortune Business Insights, the lutetium-177 market size was valued at USD 2.73 billion in 2025 and is projected to grow to USD 3.43 billion in 2026. The market is expected to reach USD 14.7 billion by 2034, registering a strong CAGR of 19.95% during the 2026-2034 forecast period.

North America dominated the global lutetium-177 market with an 80.95% market share in 2025, driven by high cancer prevalence, robust reimbursement frameworks, and the presence of large-scale Lu-177 production facilities.

Market Overview

Lutetium-177 is a radioactive isotope widely used in targeted radionuclide therapy, particularly for treating prostate cancer and neuroendocrine tumors. It delivers beta radiation directly to cancer cells by binding to specific receptors such as prostate-specific membrane antigen (PSMA), thereby minimizing damage to surrounding healthy tissues. These clinical advantages have positioned Lu-177 as a critical component of precision oncology.

The rising incidence of cancer globally, increasing demand for targeted treatments, and strong research and development pipelines from leading pharmaceutical companies are accelerating market growth. Prominent players such as Novartis AG, Lantheus Holdings, Inc., and Telix Pharmaceuticals Limited are actively investing in clinical trials and product expansion.

Market Drivers

Rising Prevalence of Cancer

The increasing burden of cancer, particularly prostate cancer and neuroendocrine tumors, is a primary driver of the lutetium-177 market. Lu-177-based therapies offer improved therapeutic precision, making them highly suitable for advanced and metastatic cancers.

For instance, according to the American Cancer Society, 313,780 new prostate cancer cases were estimated in the U.S. in 2025, highlighting the growing patient pool requiring targeted therapies and supporting market expansion.

Strong Research and Development Activity

Extensive R&D efforts and late-stage clinical trials are further propelling market growth. In December 2023, Lantheus Holdings, Inc., in collaboration with POINT Biopharma, announced positive topline results from the Phase 3 SPLASH study evaluating 177Lu-PNT2002 for metastatic castration-resistant prostate cancer, reinforcing confidence in Lu-177-based treatments.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the high cost of Lu-177 treatment, particularly in lower- and middle-income countries. Costs associated with radiopharmaceutical manufacturing, specialized facilities, regulatory compliance, and trained personnel significantly increase treatment expenses.

Additionally, limited nuclear medicine infrastructure and inadequate reimbursement policies in developing regions restrict widespread adoption.

Market Opportunities

Expansion of Clinical Applications

The increasing number of clinical trials exploring new therapeutic indications for Lu-177 presents significant growth opportunities. Regulatory approvals for new Lu-177 candidates and pediatric indications are expanding the addressable patient population.

For example, the U.S. FDA granted Rare Pediatric Disease Designation to Y-mAbs Therapeutics for 177Lu-omburtamab-DTPA, highlighting future growth potential beyond adult oncology.

Market Trends

Growth of Combination Therapies

The use of Lu-177 in combination with chemotherapy and immunotherapy is emerging as a key trend. Combination approaches enhance treatment efficacy, reduce resistance, and allow lower radiation doses. Pharmaceutical collaborations aimed at developing such therapies are gaining momentum.

Segmentation Analysis

By Drug

Based on drug type, the market is segmented into LUTATHERA, PLUVICTO, and others.

LUTATHERA (lutetium Lu 177 dotatate) held a dominant share in 2024 due to rising neuroendocrine tumor prevalence. PLUVICTO is expected to witness strong growth, supported by increasing prostate cancer cases and reimbursement approvals, such as Canada's public reimbursement decision in March 2025.

By Age Group

The adult segment dominated the market in 2024, driven by the high prevalence of prostate cancer among individuals aged 65 and above. The pediatric segment is expected to grow steadily due to regulatory approvals for pediatric use of Lu-177 therapies.

By Application

The prostate cancer segment accounted for the largest share in 2024, supported by increasing disease prevalence and product launches. The neuroendocrine tumors segment is also expected to grow notably due to rising incidence and ongoing R&D activities.

By End User

Hospitals dominated the market in 2024, owing to advanced infrastructure for handling radiopharmaceuticals and increasing collaborations with biotechnology companies. Specialty clinics and research institutes are also witnessing growing adoption.

Regional Insights

The North America lutetium-177 market was valued at USD 2.21 billion in 2025, driven by advanced healthcare infrastructure and strong reimbursement policies. The U.S. remains the largest contributor due to the presence of major manufacturers and production facilities.

Europe holds the second-largest share, supported by rising cancer cases and dedicated nuclear medicine centers. Asia Pacific is projected to be the fastest-growing region due to increasing cancer prevalence, expanding clinical trials, and growing investment in radiopharmaceutical research.

Competitive Landscape

The market is consolidated, with Novartis AG holding a significant share due to its robust product portfolio and regulatory approvals. Other key players include Telix Pharmaceuticals, Lantheus Holdings, Radiopharm Theranostics, and Curium, all actively expanding their Lu-177 pipelines.

Conclusion

The global lutetium-177 market, valued at USD 2.73 billion in 2025, is projected to grow to USD 3.43 billion in 2026 and reach USD 14.7 billion by 2034. The increasing prevalence of cancer, strong clinical pipelines, and rising adoption of targeted radionuclide therapy are expected to support sustained market growth over the forecast period.

Segmentation By Drug

  • LUTATHERA (lutetium Lu 177 dotatate)
  • PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
  • Others

By Age Group

  • Adults
  • Pediatrics

By Application

  • Neuroendocrine Tumor
  • Prostate Cancer
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America (By Drug, Age Group, Application, End-User, and Country)
    • U.S.
    • Canada
  • Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World ( By Drug, Age Group, Application, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 5.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adults
    • 5.2.2. Pediatrics
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Neuroendocrine Tumors
    • 5.3.2. Prostate Cancer
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 6.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adults
    • 6.2.2. Pediatrics
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Neuroendocrine Tumors
    • 6.3.2. Prostate Cancer
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 7.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adults
    • 7.2.2. Pediatrics
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Neuroendocrine Tumors
    • 7.3.2. Prostate Cancer
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 8.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adults
    • 8.2.2. Pediatrics
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Neuroendocrine Tumors
    • 8.3.2. Prostate Cancer
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Rest of the World Lutetium-177 Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. LUTATHERA (lutetium Lu 177 dotatate)
    • 9.1.2. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adults
    • 9.2.2. Pediatrics
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Neuroendocrine Tumors
    • 9.3.2. Prostate Cancer
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Telix Pharmaceuticals Limited
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Ariceum Therapeutics
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Radiopharm Theranostics Limited
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Lantheus Holdings, Inc.
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Y-mAbs Therapeutics, Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. GLYTHERIX
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Curium
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 2: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 3: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 4: Global Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 5: Global Lutetium-177 Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 7: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 8: North America Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: North America Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 10: North America Lutetium-177 Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 12: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 13: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 14: Europe Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 15: Europe Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 17: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 18: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 20: Asia Pacific Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 22: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 24: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 25: Rest of the World Lutetium-177 Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Lutetium-177 Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Lutetium-177 Market Value Share (%), by Drug, 2025 & 2034
  • Figure 3: Global Lutetium-177 Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 4: Global Lutetium-177 Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Lutetium-177 Market Value Share (%), by End-User, 2025 & 2034
  • Figure 6: North America Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 7: North America Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 8: North America Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 9: North America Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 10: North America Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 11: North America Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 12: North America Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 13: North America Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 14: North America Lutetium-177 Market Value (USD billion), By Country, 2025 & 2034
  • Figure 15: North America Lutetium-177 Market Value Share (%), By Country, 2025
  • Figure 16: Europe Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 17: Europe Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 18: Europe Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 19: Europe Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 20: Europe Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 21: Europe Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 22: Europe Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 23: Europe Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 24: Europe Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 25: Europe Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 26: Asia Pacific Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 27: Asia Pacific Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 28: Asia Pacific Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 29: Asia Pacific Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 30: Asia Pacific Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 31: Asia Pacific Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 32: Asia Pacific Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 33: Asia Pacific Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 34: Asia Pacific Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 35: Asia Pacific Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 36: Rest of the World Lutetium-177 Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 37: Rest of the World Lutetium-177 Market Value Share (%), by Drug, 2025
  • Figure 38: Rest of the World Lutetium-177 Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 39: Rest of the World Lutetium-177 Market Value Share (%), by Age Group, 2025
  • Figure 40: Rest of the World Lutetium-177 Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Rest of the World Lutetium-177 Market Value Share (%), by Application, 2025
  • Figure 42: Rest of the World Lutetium-177 Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 43: Rest of the World Lutetium-177 Market Value Share (%), by End-User, 2025
  • Figure 44: Rest of the World Lutetium-177 Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Rest of the World Lutetium-177 Market Value Share (%), By Country/ Sub-region, 2025

Figure 46: Global Lutetium-177 Market Share (%), By Company, 2025